Any movement is due to the silly headlines about next year's 'earnings' or 'revenues'. Those aren't important, so we only focus on the trial data coming out. We already knew about PhIII being pushed back from comments as recent ago as the FastTrack announcement. Getting some of the actual data public for us to interpret would be nice, so, if anything, it's disappointing in that we're as clueless as we were yesterday. The investor presentation next week will likely be equally worthless unless the project milestone payments.